Switch patterns in a cohort of individuals with asthma who received omalizumab or mepolizumab therapy.
作者信息
Akenroye Ayobami, Ryan Tessa, McGill Alanna, Zhou Guohai, Shier Jerome, Segal Jodi
机构信息
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
出版信息
J Allergy Clin Immunol Pract. 2023 Mar;11(3):946-948.e1. doi: 10.1016/j.jaip.2022.10.047. Epub 2022 Nov 13.
Abstract
摘要
相似文献
1
Switch patterns in a cohort of individuals with asthma who received omalizumab or mepolizumab therapy.
J Allergy Clin Immunol Pract. 2023 Mar;11(3):946-948.e1. doi: 10.1016/j.jaip.2022.10.047. Epub 2022 Nov 13.
2
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Ann Allergy Asthma Immunol. 2018 Dec;121(6):742-743. doi: 10.1016/j.anai.2018.07.030. Epub 2018 Jul 27.
3
Mepolizumab (Nucala°) in asthma.
Prescrire Int. 2017 Feb;26(179):38-39.
4
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929231. doi: 10.1177/1753466620929231.
5
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
Clin Exp Allergy. 2024 Apr;54(4):286-290. doi: 10.1111/cea.14436. Epub 2023 Dec 12.
6
Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Clin Exp Allergy. 2021 Aug;51(8):1019-1032. doi: 10.1111/cea.13882. Epub 2021 May 6.
7
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
Allergy. 2020 Apr;75(4):942-946. doi: 10.1111/all.14048. Epub 2019 Oct 2.
8
Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab.
Allergy. 2020 Apr;75(4):940-942. doi: 10.1111/all.14035. Epub 2019 Oct 3.
9
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24.
10
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
Respir Med. 2017 Feb;123:140-148. doi: 10.1016/j.rmed.2016.12.009. Epub 2016 Dec 21.
引用本文的文献
1
Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.
Respir Med. 2024 Nov-Dec;234:107802. doi: 10.1016/j.rmed.2024.107802. Epub 2024 Sep 10.
2
Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Sci Rep. 2024 May 6;14(1):10404. doi: 10.1038/s41598-024-60864-3.
3
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Allergy. 2024 May;79(5):1195-1207. doi: 10.1111/all.16002. Epub 2024 Jan 2.
本文引用的文献
1
Persistence of asthma biologic use in a US claims database.
Ann Allergy Asthma Immunol. 2021 Dec;127(6):648-654. doi: 10.1016/j.anai.2021.04.026. Epub 2021 May 7.
2
How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1081-1088. doi: 10.1016/j.jaip.2020.10.048.
3
Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
Clin Exp Allergy. 2021 Feb;51(2):221-227. doi: 10.1111/cea.13809. Epub 2020 Dec 16.
4
The Relationship of Asthma Biologics to Remission for Asthma.
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1090-1098. doi: 10.1016/j.jaip.2020.10.035. Epub 2020 Oct 28.
5
Severe asthma in the US population and eligibility for mAb therapy.
J Allergy Clin Immunol. 2020 Apr;145(4):1295-1297.e6. doi: 10.1016/j.jaci.2019.12.009. Epub 2019 Dec 19.
6
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Allergy. 2019 Sep;74(9):1716-1726. doi: 10.1111/all.13850. Epub 2019 Jul 1.
7
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
J Asthma. 2018 Feb;55(2):152-160. doi: 10.1080/02770903.2017.1322611. Epub 2017 Jun 16.
8
Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
PLoS Med. 2011 Aug;8(8):e1001075. doi: 10.1371/journal.pmed.1001075. Epub 2011 Aug 16.
Zotero 插件